Kinexus Vision
Research into cell signalling is extremely daunting due to its sheer complexity. About 20% of the approximately 20,000 genes in the human genome encode cell signalling proteins. In the post-genomics world, one of the major challenges today is defining the potential interactions among these proteins and charting regulatory protein networks. Different cell and tissue types are strikingly distinct in their patterns of regulation of these important proteins. There appears to be an excess of over a million phosphorylation sites in the human phosphoproteome. Already about 250,000 human phosphosites have been experimentally confirmed. These phosphosites are likely to prove to be a rich source of biomarkers for disease detection. The over 538 protein kinases that catalyze their phosphorylation represent important drug targets for the pharmaceutical industry. Kinexus is dedicated to the longer term prospect of defining new diagnostic tools and developing therapeutics to treat disease.
Kinexus has recently expanded its proteomics services to permit more customized work for our clients. This includes the launch of custom microarrays, peptide synthesis, protein production and mass spectrometry-based protein identification services. The offer of our Kinex™ antibody microarray and Kinetworks™ multi-immunoblotting services has been limited by the availability of high quality antibodies. Over 75% of the over 6000 commercial antibodies that we have tested are impotent or non-specific. While we will continue to search for suitable antibodies. In deployment in our proteomics services, in recent years, Kinexus has been undertaking the development of its own line of phosphorylation site and pan-specific antibodies. In addition, we are producing novel peptides as kinase substrates and inhibitors. Kinexus has now become a supplier of unique microarrays, antibodies and synthetic peptides to detect and assay signaling proteins.
To continue to develop innovative products and services, Kinexus has undertaken several important bioinformatics initiatives. We have generated over 10,000 Kinetworks™ multi-immunoblots in-house as well as 4,500 Kinex™ antibody microarray analyses to track the expression and phosphorylation of hundreds of protein kinases, phosphatases, cell cycle, stress and apopotosis proteins in thousands of different clinical samples, and tissue and cell lysates from animal experimental models. We have made most of this immunoblotting and antibody microarray data freely available to the biomedical research community in our on-line KiNET DataBank.
In 2009, we launched the first of our on-line free access SigNET Knowledgebases called PhosphoNET, which tracks human phosphorylation sites. This website has been consistently updated since then, and joined over the years with additional knowledgebases for human gene expression (TranscriptoNET), human protein kinases (KinaseNET), kinase inhibitory drugs (DrugKiNET) and human cancer proteins (OncoNET).
In addition to KiNET and SigNET, we have introduced our own Internet scientific publication called Kinetica On-line, with original research, articles and blogs from Kinexus. While all of these on-line bioinformatics services are open-access, Kinexus hopes to generate advertising revenues from commercial vendors that will sponsor these unique cyberspace resources. All of these new activities will permit Kinexus to further create and offer high definition maps of cell signalling networks to support the discovery of disease biomarkers and therapeutic drug targets. We plan to mine our databases and knowledgebases to continue to design new antibodies and peptides to expand our line of proteomics services and products and further service the biomedical research community.
We remain fully committed to providing the highest standards of service and quality products possible for our clients. Over 93 percent of our clients have rated our services as good to excellent. The integrity of the experimental results from our proteomics services is just as important to us as our customers. We consider our clients as our research partners, and we have been fortunate to have co-published scientific papers with several of our clients. We hope to enter into diagnostic and therapeutics development with our corporate clients in the future.
With the identification of the best therapeutic targets, Kinexus plans to develop novel inhibitors of selected protein kinases that can be used to manipulate signal transduction pathways for research and therapeutic purposes. One day, we shall be able to listen to cells by tapping into their communications systems to rapidly learn about the molecular lesions that underlie the most common diseases. We will exploit this information to silence these diseases by application of appropriate protein kinase inhibitors on an individual patient basis. It will be our greatest contributions to the development of personalized medicine, and it would have only been possible with the strong dedication of our employees, and the continuing support of our shareholders, clients, and collaborators.
Finally, one of our important objectives is to facilitate signal transduction research in the scientific community, in part by making this website a major educational resource and portal for cell signalling information in the Internet. We very much welcome your suggestions as to how we can be of greatest value to you.
Sincerely,
Steven Pelech, Ph.D.
Founder, President & Chief Scientific Officer
February 1, 2018
In addition to KiNET and SigNET, we have introduced our own Internet scientific publication called Kinetica On-line, with original research, articles and blogs from Kinexus. While all of these on-line bioinformatics services are open-access, Kinexus hopes to generate advertising revenues from commercial vendors that will sponsor these unique cyberspace resources. All of these new activities will permit Kinexus to further create and offer high definition maps of cell signalling networks to support the discovery of disease biomarkers and therapeutic drug targets. We plan to mine our databases and knowledgebases to continue to design new antibodies and peptides to expand our line of proteomics services and products and further service the biomedical research community.
We remain fully committed to providing the highest standards of service and quality products possible for our clients. Over 93 percent of our clients have rated our services as good to excellent. The integrity of the experimental results from our proteomics services is just as important to us as our customers. We consider our clients as our research partners, and we have been fortunate to have co-published scientific papers with several of our clients. We hope to enter into diagnostic and therapeutics development with our corporate clients in the future.
With the identification of the best therapeutic targets, Kinexus plans to develop novel inhibitors of selected protein kinases that can be used to manipulate signal transduction pathways for research and therapeutic purposes. One day, we shall be able to listen to cells by tapping into their communications systems to rapidly learn about the molecular lesions that underlie the most common diseases. We will exploit this information to silence these diseases by application of appropriate protein kinase inhibitors on an individual patient basis. It will be our greatest contributions to the development of personalized medicine, and it would have only been possible with the strong dedication of our employees, and the continuing support of our shareholders, clients, and collaborators.
Finally, one of our important objectives is to facilitate signal transduction research in the scientific community, in part by making this website a major educational resource and portal for cell signalling information in the Internet. We very much welcome your suggestions as to how we can be of greatest value to you.
Sincerely,
Steven Pelech, Ph.D.
Founder, President & Chief Scientific Officer
February 1, 2018